Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

Nearly a year ago, Viking Therapeutics (NASDAQ ... The injectable version of the candidate, tentatively named VK2735, reduced obesity patients' weight by 14.7% after 13 weeks in a relatively ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ ... results from its potential weight loss asset VK2735, which could potentially become a groundbreaking ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ ... especially impressed by the strong results from its potential weight loss asset VK2735, which could ...

Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) shares traded down 4.9% on Monday after Maxim Group lowered their price target on the stock from $120.00 to $70.00.Maxim Group currently ...